{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:41:03Z","timestamp":1792708863873,"version":"4.5.0"},"reference-count":249,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["2023xkjT012"],"award-info":[{"award-number":["2023xkjT012"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bbamcr.2026.120221","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:22:24Z","timestamp":1788823344000},"page":"120221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temozolomide resistance in glioblastoma: Multidimensional networks, core signaling hubs, and targeted therapeutic strategies"],"prefix":"10.1016","volume":"1873","author":[{"given":"Ying","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewenjing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongchao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongcui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bbamcr.2026.120221_bb0005","article-title":"Rising incidence of glioblastoma multiforme in a well-defined population","volume":"12","author":"Grech","year":"2020","journal-title":"Cureus"},{"issue":"8","key":"10.1016\/j.bbamcr.2026.120221_bb0010","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120221_bb0015","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb0020","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41418-019-0474-7","article-title":"Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients","volume":"27","author":"Mulcahy Levy","year":"2020","journal-title":"Cell Death Differ."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb0025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.trecan.2020.01.009","article-title":"Glioblastoma stem cells: driving resilience through chaos","volume":"6","author":"Prager","year":"2020","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120221_bb0030","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120221_bb0035","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: a review","volume":"329","author":"Schaff","year":"2023","journal-title":"Jama"},{"issue":"1\u20132","key":"10.1016\/j.bbamcr.2026.120221_bb0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0921-8777(01)00105-7","article-title":"Repair of O6-methylguanine is not affected by thymine base pairing and the presence of MMR proteins","volume":"487","author":"Lips","year":"2001","journal-title":"Mutat. Res."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120221_bb0045","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1096\/fasebj.6.6.1544541","article-title":"Repair of DNA containing O6-alkylguanine","volume":"6","author":"Pegg","year":"1992","journal-title":"FASEB J."},{"issue":"Pt 2","key":"10.1016\/j.bbamcr.2026.120221_bb0050","article-title":"Novel strategies to overcome chemoresistance in human glioblastoma","volume":"230","author":"Tang","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120221_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188616","article-title":"Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance","volume":"1876","author":"Tomar","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"27","key":"10.1016\/j.bbamcr.2026.120221_bb0060","article-title":"EGFR-induced and c-Src-mediated CD47 phosphorylation inhibits TRIM21-dependent polyubiquitylation and degradation of CD47 to promote tumor immune evasion","volume":"10","author":"Du","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"issue":"18","key":"10.1016\/j.bbamcr.2026.120221_bb0065","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1007\/s00018-014-1608-1","article-title":"EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy","volume":"71","author":"Zahonero","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"issue":"32","key":"10.1016\/j.bbamcr.2026.120221_bb0070","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2303400120","article-title":"SEC61G assists EGFR-amplified glioblastoma to evade immune elimination","volume":"120","author":"Zeng","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"734","key":"10.1016\/j.bbamcr.2026.120221_bb0075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj5962","article-title":"Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization","volume":"16","author":"Chen","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb0080","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41418-018-0126-3","article-title":"TP53 gain-of-function mutation promotes inflammation in glioblastoma","volume":"26","author":"Ham","year":"2019","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0085","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fonc.2019.00417","article-title":"Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics","volume":"9","author":"Golub","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0090","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00401-018-1849-4","article-title":"Novel, improved grading system(s) for IDH-mutant astrocytic gliomas","volume":"136","author":"Shirahata","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"9","key":"10.1016\/j.bbamcr.2026.120221_bb0095","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.celrep.2017.05.012","article-title":"2-HG inhibits necroptosis by stimulating DNMT1-dependent hypermethylation of the RIP3 promoter","volume":"19","author":"Yang","year":"2017","journal-title":"Cell Rep."},{"issue":"18","key":"10.1016\/j.bbamcr.2026.120221_bb0100","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1158\/1078-0432.CCR-24-1056","article-title":"Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma","volume":"30","author":"Grewal","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s40478-024-01837-5","article-title":"Distinct tumor-TAM interactions in IDH-stratified glioma microenvironments unveiled by single-cell and spatial transcriptomics","volume":"12","author":"Motevasseli","year":"2024","journal-title":"Acta Neuropathol. Commun."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120221_bb0110","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/10408363.2018.1462759","article-title":"Sequencing the next generation of glioblastomas","volume":"55","author":"Jov\u010devska","year":"2018","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s10014-023-00473-6","article-title":"FISH analysis reveals CDKN2A and IFNA14 co-deletion is heterogeneous and is a prominent feature of glioblastoma","volume":"41","author":"Al Shboul","year":"2024","journal-title":"Brain Tumor Pathol."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120221_bb0120","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ccell.2023.05.001","article-title":"CDKN2A deletion remodels lipid metabolism to prime glioblastoma for ferroptosis","volume":"41","author":"Minami","year":"2023","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120221_bb0125","first-page":"2102","article-title":"MDM2\/MDM4 amplification and CDKN2A deletion in metastatic melanoma and glioblastoma multiforme may have implications for targeted therapeutics and immunotherapy","volume":"12","author":"Arnoff","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120221_bb0130","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"13","key":"10.1016\/j.bbamcr.2026.120221_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137148","article-title":"MGMT and whole-genome DNA methylation impacts on diagnosis, prognosis and therapy of glioblastoma multiforme","volume":"23","author":"Della Monica","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0140","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13148-023-01608-4","article-title":"Histone demethylase KDM4B accelerates the progression of glioblastoma via the epigenetic regulation of MYC stability","volume":"15","author":"Wang","year":"2023","journal-title":"Clin. Epigenetics"},{"issue":"7942","key":"10.1016\/j.bbamcr.2026.120221_bb0145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41586-022-05551-x","article-title":"BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network","volume":"613","author":"Sun","year":"2023","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120221_bb0150","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41419-023-05959-x","article-title":"MGCG regulates glioblastoma tumorigenicity via hnRNPK\/ATG2A and promotes autophagy","volume":"14","author":"Chu","year":"2023","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.bbamcr.2026.120221_bb0155","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/neuonc\/noae036","article-title":"Long non-coding RNA lung cancer-associated transcript-1 promotes glioblastoma progression by enhancing Hypoxia-inducible factor 1 alpha activity","volume":"26","author":"Huang","year":"2024","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbamcr.2026.120221_bb0160","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bbrc.2023.05.057","article-title":"miR-491-5p regulates the susceptibility of glioblastoma to ferroptosis through TP53","volume":"671","author":"Jie","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216467","article-title":"Histone lactylation-derived LINC01127 promotes the self-renewal of glioblastoma stem cells via the cis-regulating the MAP4K4 to activate JNK pathway","volume":"579","author":"Li","year":"2023","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.bbamcr.2026.120221_bb0170","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/cam4.775","article-title":"MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics","volume":"5","author":"Shea","year":"2016","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0175","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1947601909356103","article-title":"Epigenetic regulation of wnt pathway antagonists in human glioblastoma multiforme","volume":"1","author":"Foltz","year":"2010","journal-title":"Genes Cancer"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0180","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-024-01563-4","article-title":"Wnt\/\u03b2-catenin signaling pathway in carcinogenesis and cancer therapy","volume":"17","author":"Song","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0185","doi-asserted-by":"crossref","DOI":"10.1177\/09636897221134540","article-title":"Wif1 mediates coordination of bone morphogenetic protein and Wnt Signaling in neural and glioma stem cells","volume":"31","author":"Xu","year":"2022","journal-title":"Cell Transplant."},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120221_bb0190","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/modpathol.2012.215","article-title":"Promoter methylation of WNT inhibitory factor-1 and expression pattern of WNT\/\u03b2-catenin pathway in human astrocytoma: pathologic and prognostic correlations","volume":"26","author":"Kim","year":"2013","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0195","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fcell.2018.00167","article-title":"An eye on the Wnt inhibitory factor Wif1","volume":"6","author":"Poggi","year":"2018","journal-title":"Front. Cell Dev. Biol."},{"issue":"9","key":"10.1016\/j.bbamcr.2026.120221_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002368","article-title":"Wnt target gene activation requires \u03b2-catenin separation into biomolecular condensates","volume":"22","author":"Stewart","year":"2024","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116920","article-title":"Targeting the interaction of \u03b2-catenin and TCF\/LEF transcription factors to inhibit oncogenic Wnt signaling","volume":"70","author":"Koelman","year":"2022","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120221_bb0210","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1111\/jcmm.14083","article-title":"HPCAL1 promotes glioblastoma proliferation via activation of Wnt\/\u03b2-catenin signalling pathway","volume":"23","author":"Zhang","year":"2019","journal-title":"J. Cell. Mol. Med."},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120221_bb0215","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1111\/jcmm.15189","article-title":"SOX9-activated PXN-AS1 promotes the tumorigenesis of glioblastoma by EZH2-mediated methylation of DKK1","volume":"24","author":"Chen","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.111055","article-title":"Targeting PI3K\/AKT\/mTOR signaling to overcome drug resistance in cancer","volume":"396","author":"Tufail","year":"2024","journal-title":"Chem. Biol. Interact."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120221_bb0225","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12032-025-02652-1","article-title":"Targeting EGFR and PI3K\/mTOR pathways in glioblastoma: innovative therapeutic approaches","volume":"42","author":"Singh","year":"2025","journal-title":"Med. Oncol."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120221_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095219","article-title":"Activation of the PI3K\/mTOR\/AKT pathway and survival in solid tumors: systematic review and meta-analysis","volume":"9","author":"Ocana","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120221_bb0235","first-page":"731","article-title":"Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility","volume":"35","author":"Gulati","year":"2009","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0240","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.pathol.4.110807.092311","article-title":"PTEN and the PI3-kinase pathway in cancer","volume":"4","author":"Chalhoub","year":"2009","journal-title":"Annu. Rev. Pathol."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb0245","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.tips.2010.12.005","article-title":"Non-genomic loss of PTEN function in cancer: not in my genes","volume":"32","author":"Leslie","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0250","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","article-title":"Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance","volume":"59","author":"Ediriweera","year":"2019","journal-title":"Semin. Cancer Biol."},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120221_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/cells10113065","article-title":"PI3K pathway inhibition with NVP-BEZ235 hinders glycolytic metabolism in glioblastoma multiforme cells","volume":"10","author":"Udawant","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bbamcr.2026.120221_bb0260","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","article-title":"PI3K\/AKT\/mTOR pathway in angiogenesis","volume":"4","author":"Karar","year":"2011","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0265","doi-asserted-by":"crossref","first-page":"110350","DOI":"10.1016\/j.cellsig.2022.110350","article-title":"Crosstalk between PI3K\/AKT\/mTOR and WNT\/\u03b2-catenin signaling in GBM - could combination therapy checkmate the collusion?","volume":"95","author":"Daisy Precilla","year":"2022","journal-title":"Cell. Signal."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120221_bb0270","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2023.5558","article-title":"NQO1 drives glioblastoma cell aggressiveness through EMT induction via the PI3K\/Akt\/mTOR\/Snail pathway","volume":"63","author":"Zheng","year":"2023","journal-title":"Int. J. Oncol."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120221_bb0275","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3350\/cmh.2019.0056n","article-title":"Inhibition of PI3K\/Akt signaling suppresses epithelial-to-mesenchymal transition in hepatocellular carcinoma through the Snail\/GSK-3\/beta-catenin pathway","volume":"26","author":"Lee","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb0280","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41419-024-06569-x","article-title":"OTUD4 promotes the progression of glioblastoma by deubiquitinating CDK1 and activating MAPK signaling pathway","volume":"15","author":"Ci","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120307","article-title":"GPR17 signaling activation by CHBC agonist induced cell death via modulation of MAPK pathway in glioblastoma","volume":"291","author":"Nguyen","year":"2022","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188736","article-title":"E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers","volume":"1877","author":"Park","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120221_bb0295","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.3390\/cimb45040222","article-title":"AKR1B1 represses glioma cell proliferation through p38 MAPK-mediated Bcl-2\/BAX\/caspase-3 apoptotic signaling pathwayS","volume":"45","author":"Huang","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119499","article-title":"Interplay between MAPK\/ERK signaling pathway and MicroRNAs: a crucial mechanism regulating cancer cell metabolism and tumor progression","volume":"278","author":"Asl","year":"2021","journal-title":"Life Sci."},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120221_bb0305","doi-asserted-by":"crossref","first-page":"625","DOI":"10.4161\/cbt.24595","article-title":"Level of notch activation determines the effect on growth and stem cell-like features in glioblastoma multiforme neurosphere cultures","volume":"14","author":"Kristoffersen","year":"2013","journal-title":"Cancer Biol. Ther."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120221_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/biom10060886","article-title":"Leptin and notch signaling cooperate in sustaining glioblastoma multiforme progression","volume":"10","author":"Panza","year":"2020","journal-title":"Biomolecules"},{"issue":"12","key":"10.1016\/j.bbamcr.2026.120221_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210094","article-title":"Cdk4 regulates glioblastoma cell invasion and stemness and is target of a notch inhibitor plus resveratrol combined treatment","volume":"24","author":"Giordano","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120221_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00431","article-title":"Pyrimidine compounds BY4003 and BY4008 inhibit glioblastoma cells growth via modulating JAK3\/STAT3 signaling pathway","volume":"21","author":"Ahmad","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.bbamcr.2026.120221_bb0325","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.736941","article-title":"RBM8A promotes glioblastoma growth and invasion through the Notch\/STAT3 pathway","volume":"11","author":"Lin","year":"2021","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.bbamcr.2026.120221_bb0330","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/s41590-023-01605-y","article-title":"Kunitz-type protease inhibitor TFPI2 remodels stemness and immunosuppressive tumor microenvironment in glioblastoma","volume":"24","author":"Pang","year":"2023","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb0335","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nm1379","article-title":"Roots and stems: stem cells in cancer","volume":"12","author":"Polyak","year":"2006","journal-title":"Nat. Med."},{"issue":"6190","key":"10.1016\/j.bbamcr.2026.120221_bb0340","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"Patel","year":"2014","journal-title":"Science"},{"issue":"50","key":"10.1016\/j.bbamcr.2026.120221_bb0345","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.1038\/s41388-020-01503-9","article-title":"Megalencephalic leukoencephalopathy with subcortical cysts 1 (MLC1) promotes glioblastoma cell invasion in the brain microenvironment","volume":"39","author":"Lattier","year":"2020","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.bbamcr.2026.120221_bb0350","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/neuonc\/noad134","article-title":"Stationary-to-migratory transition in glioblastoma stem-like cells driven by a fatty acid-binding protein 7-RXR\u03b1 neurogenic pathway","volume":"25","author":"Liu","year":"2023","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0355","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cell.2013.02.021","article-title":"Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth","volume":"153","author":"Cheng","year":"2013","journal-title":"Cell"},{"issue":"7325","key":"10.1016\/j.bbamcr.2026.120221_bb0360","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nature09557","article-title":"Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells","volume":"468","author":"Ricci-Vitiani","year":"2010","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11030292","article-title":"Role of notch signaling pathway in glioblastoma pathogenesis","volume":"11","author":"Bazzoni","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.bbamcr.2026.120221_bb0370","doi-asserted-by":"crossref","DOI":"10.3390\/genes15121597","article-title":"Wnt signaling pathway in tumor biology","volume":"15","author":"Iluta","year":"2024","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.bbamcr.2026.120221_bb0375","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3389\/fncel.2017.00318","article-title":"Targeting WNT signaling for multifaceted glioblastoma therapy","volume":"11","author":"McCord","year":"2017","journal-title":"Front. Cell. Neurosci."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16010102","article-title":"Progress in glioma stem cell research","volume":"16","author":"Ramar","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"31","key":"10.1016\/j.bbamcr.2026.120221_bb0385","article-title":"Perivascular stromal cells instruct glioblastoma invasion, proliferation, and therapeutic response within an engineered brain perivascular niche model","volume":"9","author":"Ngo","year":"2022","journal-title":"Adv. Sci. (Weinh)"},{"issue":"21","key":"10.1016\/j.bbamcr.2026.120221_bb0390","article-title":"Investigating the interactions of glioma stem cells in the perivascular niche at single-cell resolution using a microfluidic tumor microenvironment model","volume":"9","author":"Adjei-Sowah","year":"2022","journal-title":"Adv. Sci. (Weinh)"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120221_bb0395","doi-asserted-by":"crossref","first-page":"665","DOI":"10.7150\/thno.41692","article-title":"Glioma stem cells and their roles within the hypoxic tumor microenvironment","volume":"11","author":"Boyd","year":"2021","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.bbamcr.2026.120221_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101137","article-title":"Hypoxia-induced phenotypic transition from highly invasive to less invasive tumors in glioma stem-like cells: Significance of CD44 and osteopontin as therapeutic targets in glioblastoma","volume":"14","author":"Nishikawa","year":"2021","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0405","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12935-024-03335-z","article-title":"Unravelling immune microenvironment features underlying tumor progression in the single-cell era","volume":"24","author":"Du","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216714","article-title":"From lymphopenia to restoration: IL-7 immunotherapy for lymphocyte recovery in glioblastoma","volume":"588","author":"Kim","year":"2024","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0415","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1038\/s41467-019-09853-z","article-title":"Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment","volume":"10","author":"Dirkse","year":"2019","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120221_bb0420","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1111\/cas.15773","article-title":"Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma","volume":"114","author":"Wu","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0425","doi-asserted-by":"crossref","first-page":"9628289","DOI":"10.1155\/2018\/9628289","article-title":"Association of glioblastoma multiforme stem cell characteristics, differentiation, and microglia marker genes with patient survival","volume":"2018","author":"Bien-M\u00f6ller","year":"2018","journal-title":"Stem Cells Int."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120221_bb0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172791","article-title":"Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity","volume":"12","author":"Brown","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120221_bb0435","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncb2152","article-title":"AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1","volume":"13","author":"Kim","year":"2011","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb0440","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/15548627.2020.1731266","article-title":"Hypoxia-induced acetylation of PAK1 enhances autophagy and promotes brain tumorigenesis via phosphorylating ATG5","volume":"17","author":"Feng","year":"2021","journal-title":"Autophagy"},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb0445","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/15548627.2021.1946739","article-title":"RAB7 activity is required for the regulation of mitophagy in oocyte meiosis and oocyte quality control during ovarian aging","volume":"18","author":"Jin","year":"2022","journal-title":"Autophagy"},{"key":"10.1016\/j.bbamcr.2026.120221_bb0450","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8281718","article-title":"Oleanolic acid induces autophagy and apoptosis via the AMPK-mTOR signaling pathway in colon cancer","volume":"2021","author":"Hu","year":"2021","journal-title":"J. Oncol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0455","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41420-024-02011-5","article-title":"AMPK-a key factor in crosstalk between tumor cell energy metabolism and immune microenvironment?","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101671","article-title":"HIF-1\u03b1-BNIP3-mediated mitophagy in tubular cells protects against renal ischemia\/reperfusion injury","volume":"36","author":"Fu","year":"2020","journal-title":"Redox Biol."},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120221_bb0465","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1158\/0008-5472.CAN-11-3831","article-title":"Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma","volume":"72","author":"Hu","year":"2012","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120221_bb0470","doi-asserted-by":"crossref","first-page":"835","DOI":"10.4161\/auto.6.7.13335","article-title":"A matter of balance between life and death: targeting reactive oxygen species (ROS)-induced autophagy for cancer therapy","volume":"6","author":"Gibson","year":"2010","journal-title":"Autophagy"},{"issue":"10","key":"10.1016\/j.bbamcr.2026.120221_bb0475","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019103111","article-title":"ATM-CHK2-Beclin 1 axis promotes autophagy to maintain ROS homeostasis under oxidative stress","volume":"39","author":"Guo","year":"2020","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120221_bb0480","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.3390\/ijms15023145","article-title":"Autophagic cell death and cancer","volume":"15","author":"Shimizu","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0485","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jconrel.2023.12.032","article-title":"Autophagy-modulating biomembrane nanostructures: a robust anticancer weapon by modulating the inner and outer cancer environment","volume":"366","author":"Zhang","year":"2024","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120221_bb0490","article-title":"KDELC2 upregulates glioblastoma angiogenesis via reactive oxygen species activation and tumor-associated macrophage proliferation","volume":"12","author":"Tsai","year":"2023","journal-title":"Antioxidants (Basel)"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0495","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11060-021-03896-3","article-title":"ERK inhibition in glioblastoma is associated with autophagy activation and tumorigenesis suppression","volume":"156","author":"Yang","year":"2022","journal-title":"J. Neuro-Oncol."},{"issue":"16","key":"10.1016\/j.bbamcr.2026.120221_bb0500","doi-asserted-by":"crossref","DOI":"10.1172\/JCI141083","article-title":"SLIT2\/ROBO signaling in tumor-associated microglia and macrophages drives glioblastoma immunosuppression and vascular dysmorphia","volume":"131","author":"Geraldo","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0505","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nn.4185","article-title":"The role of microglia and macrophages in glioma maintenance and progression","volume":"19","author":"Hambardzumyan","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0510","article-title":"The role of myeloid cells in GBM immunosuppression","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0515","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00018-025-05642-8","article-title":"Targeting HIF-2\u03b1 in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade","volume":"82","author":"Espinoza","year":"2025","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0520","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","article-title":"Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives","volume":"17","author":"Lin","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0525","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.770561","article-title":"Immunosuppression in glioblastoma: current understanding and therapeutic implications","volume":"11","author":"Himes","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0530","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14566","article-title":"PVT1 promotes proliferation and macrophage immunosuppressive polarization through STAT1 and CX3CL1 regulation in glioblastoma multiforme","volume":"30","author":"Huang","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.110109","article-title":"Deguelin inhibits the glioblastoma progression through suppressing CCL2\/NF\u03baB signaling pathway","volume":"259","author":"Qian","year":"2024","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120221_bb0540","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1215\/S1152851705000232","article-title":"The role of pericytes in blood-vessel formation and maintenance","volume":"7","author":"Bergers","year":"2005","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0545","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13046-024-03025-8","article-title":"GPR65 sensing tumor-derived lactate induces HMGB1 release from TAM via the cAMP\/PKA\/CREB pathway to promote glioma progression","volume":"43","author":"Yan","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120221_bb0550","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/2767-9764.CRC-23-0334","article-title":"PTP4A2 promotes glioblastoma progression and macrophage polarization under microenvironmental pressure","volume":"4","author":"Chouleur","year":"2024","journal-title":"Cancer Res Commun."},{"issue":"10","key":"10.1016\/j.bbamcr.2026.120221_bb0555","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/neuonc\/noae126","article-title":"IL-13R\u03b12\/TGF-\u03b2 bispecific CAR-T cells counter TGF-\u03b2-mediated immune suppression and potentiate anti-tumor responses in glioblastoma","volume":"26","author":"Hou","year":"2024","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0560","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41467-025-68112-6","article-title":"Intrathecal CRISPR-edited allogeneic IL-13R\u03b12 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial","volume":"17","author":"Li","year":"2026","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120221_bb0565","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s10147-014-0769-0","article-title":"A Phase III study of radiation therapy (RT) and O6-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001","volume":"20","author":"Blumenthal","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb0570","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/neuonc\/noaf001","article-title":"KL-50: a novel therapeutic agent targeting MGMT-deficient glioblastoma","volume":"27","author":"Zhang","year":"2025","journal-title":"Neuro-Oncology"},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120221_bb0575","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000672","article-title":"Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib\/II, open-label, multicentre, randomised study","volume":"5","author":"Rosenthal","year":"2020","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.bbamcr.2026.120221_bb0580","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1080\/15548627.2020.1816343","article-title":"Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial","volume":"17","author":"Compter","year":"2021","journal-title":"Autophagy"},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120221_bb0585","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1002\/cam4.5297","article-title":"A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: a report from the national pediatric cancer foundation","volume":"12","author":"Metts","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0590","series-title":"medRxiv","article-title":"Single nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of combined CDK4\/6 and mTOR inhibition in a phase 0\/1 trial of recurrent high-grade glioma","author":"Johnson","year":"2024"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0595","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-71362-7","article-title":"L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I\/II GLORIA trial","volume":"17","author":"Giordano","year":"2026","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120221_bb0600","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1634\/theoncologist.5-2-144","article-title":"Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma","volume":"5","author":"Agarwala","year":"2000","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0605","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0305-7372(97)90019-0","article-title":"Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials","volume":"23","author":"Newlands","year":"1997","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"10.1016\/j.bbamcr.2026.120221_bb0610","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/15384047.2019.1599662","article-title":"Glioblastoma vs temozolomide: can the red queen race be won?","volume":"20","author":"Arora","year":"2019","journal-title":"Cancer Biol. Ther."},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120221_bb0615","first-page":"1957","article-title":"p53 effects both the duration of G2\/M arrest and the fate of temozolomide-treated human glioblastoma cells","volume":"61","author":"Hirose","year":"2001","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.bbamcr.2026.120221_bb0620","first-page":"5815","article-title":"Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9\/3 regulated and Fas\/caspase-8 independent","volume":"60","author":"Ochs","year":"2000","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.bbamcr.2026.120221_bb0625","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0630","doi-asserted-by":"crossref","DOI":"10.1177\/10732748231169149","article-title":"Brain tumor radiogenomic classification of O6-methylguanine-DNA methyltransferase promoter methylation in malignant gliomas-based transfer learning","volume":"30","author":"Sakly","year":"2023","journal-title":"Cancer Control"},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120221_bb0635","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13060999","article-title":"MGMT promoter methylation: prognostication beyond treatment response","volume":"13","author":"Ashkan","year":"2023","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100929","article-title":"Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma","volume":"44","author":"Han","year":"2023","journal-title":"Neoplasia"},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120221_bb0645","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/neuonc\/noab003","article-title":"PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma","volume":"23","author":"Wu","year":"2021","journal-title":"Neuro-Oncology"},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120221_bb0650","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1001\/jamaoncol.2023.0990","article-title":"Association of MGMT promoter methylation with survival in low-grade and anaplastic gliomas after alkylating chemotherapy","volume":"9","author":"Kinslow","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154933","article-title":"Quercetin induces MGMT(+) glioblastoma cells apoptosis via dual inhibition of Wnt3a\/\u03b2-Catenin and Akt\/NF-\u03baB signaling pathways","volume":"118","author":"Wang","year":"2023","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120221_bb0660","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/jnc.14262","article-title":"Repair gene O6-methylguanine-DNA methyltransferase is controlled by SP1 and up-regulated by glucocorticoids, but not by temozolomide and radiation","volume":"144","author":"Aasland","year":"2018","journal-title":"J. Neurochem."},{"issue":"10","key":"10.1016\/j.bbamcr.2026.120221_bb0665","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.153","article-title":"BMP2 sensitizes glioblastoma stem-like cells to temozolomide by affecting HIF-1\u03b1 stability and MGMT expression","volume":"3","author":"Persano","year":"2012","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120221_bb0670","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/2159-8290.CD-19-0069","article-title":"Combined MAPK pathway and HDAC inhibition breaks melanoma","volume":"9","author":"Lombard","year":"2019","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120221_bb0675","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41419-022-05056-5","article-title":"Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p\/MGMT axis in glioma","volume":"13","author":"Geng","year":"2022","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb0680","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s12017-020-08592-5","article-title":"Overexpression miR-486-3p promoted by allicin enhances temozolomide sensitivity in glioblastoma via targeting MGMT","volume":"22","author":"Wu","year":"2020","journal-title":"NeuroMolecular Med."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120221_bb0685","doi-asserted-by":"crossref","first-page":"504","DOI":"10.5114\/aoms.2017.69374","article-title":"MiR-21, miR-34a, miR-125b, miR-181d and miR-648 levels inversely correlate with MGMT and TP53 expression in primary glioblastoma patients","volume":"15","author":"Jesionek-Kupnicka","year":"2019","journal-title":"Arch. Med. Sci."},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120221_bb0690","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1093\/neuonc\/noad102","article-title":"EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT","volume":"25","author":"Xin","year":"2023","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0695","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1073\/pnas.1314469111","article-title":"mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy","volume":"111","author":"Weiler","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120221_bb0700","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1021\/acsmedchemlett.0c00014","article-title":"Design of first-in-class dual EZH2\/HDAC inhibitor: biochemical activity and biological evaluation in cancer cells","volume":"11","author":"Romanelli","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"19","key":"10.1016\/j.bbamcr.2026.120221_bb0705","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914865","article-title":"CRISPR\/dCas9 tools: epigenetic mechanism and application in gene transcriptional regulation","volume":"24","author":"Cai","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb0710","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/neuonc\/noae257","article-title":"The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma","volume":"27","author":"McCord","year":"2025","journal-title":"Neuro-Oncology"},{"issue":"27","key":"10.1016\/j.bbamcr.2026.120221_bb0715","doi-asserted-by":"crossref","first-page":"18241","DOI":"10.1021\/jacs.3c06483","article-title":"Mechanism of action of KL-50, a candidate imidazotetrazine for the treatment of drug-resistant brain cancers","volume":"146","author":"Huseman","year":"2024","journal-title":"J. Am. Chem. Soc."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120221_bb0720","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/cam4.1384","article-title":"Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma","volume":"7","author":"Cai","year":"2018","journal-title":"Cancer Med."},{"issue":"10","key":"10.1016\/j.bbamcr.2026.120221_bb0725","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1158\/0008-5472.CAN-18-2170","article-title":"Temozolomide treatment induces lncRNA MALAT1 in an NF-\u03baB and p53 codependent manner in glioblastoma","volume":"79","author":"Voce","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115726","article-title":"Modulating MGMT expression through interfering with cell signaling pathways","volume":"215","author":"Bai","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101122","article-title":"Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma","volume":"76","author":"Lan","year":"2024","journal-title":"Drug Resist. Updat."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120221_bb0740","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/1570159X18666200626204005","article-title":"Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications","volume":"19","author":"Ortiz","year":"2021","journal-title":"Curr. Neuropharmacol."},{"issue":"8","key":"10.1016\/j.bbamcr.2026.120221_bb0745","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1158\/0008-5472.CAN-06-0127","article-title":"A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy","volume":"66","author":"Hunter","year":"2006","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120221_bb0750","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1158\/1078-0432.CCR-06-2149","article-title":"Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment","volume":"13","author":"Cahill","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120221_bb0755","doi-asserted-by":"crossref","DOI":"10.1172\/JCI195189","article-title":"Mismatch repair deficiency drives malignant progression and alters the tumor immune microenvironment in glioblastoma models","volume":"136","author":"Puigdelloses Vallcorba","year":"2026","journal-title":"J. Clin. Invest."},{"issue":"7804","key":"10.1016\/j.bbamcr.2026.120221_bb0760","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","article-title":"Mechanisms and therapeutic implications of hypermutation in gliomas","volume":"580","author":"Touat","year":"2020","journal-title":"Nature"},{"issue":"6167","key":"10.1016\/j.bbamcr.2026.120221_bb0765","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.1239947","article-title":"Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma","volume":"343","author":"Johnson","year":"2014","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.bbamcr.2026.120221_bb0770","doi-asserted-by":"crossref","DOI":"10.18103\/mra.v13i9.6944","article-title":"Novel strategies for improved treatment of O6-methylguanine-DNA methyltransferase promoter-methylated glioma","volume":"13","author":"Vasquez","year":"2025","journal-title":"Med. Res. Arch."},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120221_bb0775","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/stem.415","article-title":"Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma","volume":"28","author":"Pistollato","year":"2010","journal-title":"Stem Cells"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120221_bb0780","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","article-title":"Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance","volume":"20","author":"Liau","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bbamcr.2026.120221_bb0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106568","article-title":"Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents","volume":"187","author":"Hashemi","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0790","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12885-016-2231-3","article-title":"Relevance of miR-21 in regulation of tumor suppressor gene PTEN in human cervical cancer cells","volume":"16","author":"Peralta-Zaragoza","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbamcr.2026.120221_bb0795","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ebiom.2019.03.016","article-title":"Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma","volume":"42","author":"Yin","year":"2019","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120221_bb0800","doi-asserted-by":"crossref","DOI":"10.3390\/cells10020202","article-title":"Beyond the Warburg effect: oxidative and glycolytic phenotypes coexist within the metabolic heterogeneity of glioblastoma","volume":"10","author":"Duraj","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bbamcr.2026.120221_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216078","article-title":"RBBP4 regulates the expression of the Mre11-Rad50-NBS1 (MRN) complex and promotes DNA double-strand break repair to mediate glioblastoma chemoradiotherapy resistance","volume":"557","author":"Li","year":"2023","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0810","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40164-024-00519-1","article-title":"Feedback loop between hypoxia and energy metabolic reprogramming aggravates the radioresistance of cancer cells","volume":"13","author":"Shi","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120221_bb0815","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1158\/2159-8290.CD-20-0057","article-title":"Tumor microenvironment is critical for the maintenance of cellular states found in primary glioblastomas","volume":"10","author":"Pine","year":"2020","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120221_bb0820","article-title":"Adapt to Persist: glioblastoma microenvironment and epigenetic regulation on cell plasticity","volume":"11","author":"Uribe","year":"2022","journal-title":"Biol.-Basel"},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120221_bb0825","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10571-019-00771-8","article-title":"Glioblastoma stem cell-derived exosomes enhance stemness and tumorigenicity of glioma cells by transferring Notch1 protein","volume":"40","author":"Sun","year":"2020","journal-title":"Cell. Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0830","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120221_bb0835","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.bbamcr.2026.120221_bb0840","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1101\/gad.17558811","article-title":"The dynamic nature of autophagy in cancer","volume":"25","author":"Kimmelman","year":"2011","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0845","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12943-020-1138-4","article-title":"Autophagy and autophagy-related proteins in cancer","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbamcr.2026.120221_bb0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101170","article-title":"Autophagy in cancer development, immune evasion, and drug resistance","volume":"78","author":"Niu","year":"2025","journal-title":"Drug Resist. Updat."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120221_bb0855","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cell.2011.10.026","article-title":"Autophagy: renovation of cells and tissues","volume":"147","author":"Mizushima","year":"2011","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120221_bb0860","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrm.2017.95","article-title":"AMPK: Guardian of metabolism and mitochondrial homeostasis","volume":"19","author":"Herzig","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb0865","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-inducible factors in physiology and medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0870","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1038\/s41598-017-03230-w","article-title":"TRPC5-induced autophagy promotes drug resistance in breast carcinoma via CaMKK\u03b2\/AMPK\u03b1\/mTOR pathway","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.bbamcr.2026.120221_bb0875","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41419-020-02988-8","article-title":"Wnt\/\u03b2-catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma","volume":"11","author":"Yun","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0880","doi-asserted-by":"crossref","first-page":"1093558","DOI":"10.3389\/fimmu.2023.1093558","article-title":"The relationship between autophagy and PD-L1 and their role in antitumor therapy","volume":"14","author":"Cui","year":"2023","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.bbamcr.2026.120221_bb0885","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/onc.2016.333","article-title":"Autophagy in cancer metastasis","volume":"36","author":"Mowers","year":"2017","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120221_bb0890","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41419-022-05112-0","article-title":"XAF1 drives apoptotic switch of endoplasmic reticulum stress response through destabilization of GRP78 and CHIP","volume":"13","author":"Lee","year":"2022","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0895","article-title":"XAF1 directs glioma response to temozolomide through apoptotic transition of autophagy by activation of ATM-AMPK signaling","volume":"4","author":"Lee","year":"2022","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0900","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.biochi.2025.01.013","article-title":"The pentose phosphate pathway (PPP) in the glioma metabolism: a potent enhancer of malignancy","volume":"232","author":"Trejo-Sol\u00eds","year":"2025","journal-title":"Biochimie"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0905","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13046-025-03361-3","article-title":"PHGDH activation fuels glioblastoma progression and radioresistance via serine synthesis pathway","volume":"44","author":"Liu","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120221_bb0910","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41419-022-05044-9","article-title":"High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1\/MRP1 upregulation","volume":"13","author":"de Souza","year":"2022","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.bbamcr.2026.120221_bb0915","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2024.07.011","article-title":"Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma","volume":"36","author":"Li","year":"2024","journal-title":"Cell Metab."},{"issue":"8","key":"10.1016\/j.bbamcr.2026.120221_bb0920","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/neuonc\/noq052","article-title":"mTOR signaling in glioblastoma: lessons learned from bench to bedside","volume":"12","author":"Akhavan","year":"2010","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0925","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.molcel.2017.05.030","article-title":"mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the cystine-glutamate antiporter xCT","volume":"67","author":"Gu","year":"2017","journal-title":"Mol. Cell"},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120221_bb0930","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41588-020-00726-6","article-title":"Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity","volume":"52","author":"Kinker","year":"2020","journal-title":"Nat. Genet."},{"issue":"24","key":"10.1016\/j.bbamcr.2026.120221_bb0935","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1007\/s00018-020-03569-w","article-title":"Metabolic heterogeneity and adaptability in brain tumors","volume":"77","author":"Badr","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0940","doi-asserted-by":"crossref","first-page":"1561388","DOI":"10.3389\/fimmu.2025.1561388","article-title":"Single-cell and spatial transcriptomic insights into glioma cellular heterogeneity and metabolic adaptations","volume":"16","author":"Fu","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0945","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s40478-023-01604-y","article-title":"Compensatory cross-talk between autophagy and glycolysis regulates senescence and stemness in heterogeneous glioblastoma tumor subpopulations","volume":"11","author":"Martell","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"issue":"19","key":"10.1016\/j.bbamcr.2026.120221_bb0950","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194910","article-title":"The GBM tumor microenvironment as a modulator of therapy response: ADAM8 causes tumor infiltration of tams through HB-EGF\/EGFR-mediated CCL2 expression and overcomes TMZ chemosensitization in glioblastoma","volume":"14","author":"Liu","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6288","key":"10.1016\/j.bbamcr.2026.120221_bb0955","doi-asserted-by":"crossref","DOI":"10.1126\/science.aad3018","article-title":"The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas","volume":"352","author":"Quail","year":"2016","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120221_bb0960","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/s41419-020-03150-0","article-title":"The HIF1\u03b1\/HIF2\u03b1-miR210-3p network regulates glioblastoma cell proliferation, dedifferentiation and chemoresistance through EGF under hypoxic conditions","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0965","article-title":"Hypoxia-driven M2-polarized macrophages facilitate cancer aggressiveness and temozolomide resistance in glioblastoma","volume":"2022","author":"Zhang","year":"2022","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"10","key":"10.1016\/j.bbamcr.2026.120221_bb0970","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41422-021-00528-3","article-title":"Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling","volume":"31","author":"Zhang","year":"2021","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0975","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1186\/s12967-024-05301-9","article-title":"The tumour microenvironment, treatment resistance and recurrence in glioblastoma","volume":"22","author":"White","year":"2024","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0980","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13046-019-1139-6","article-title":"Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma","volume":"38","author":"Zhang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb0985","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s13046-022-02431-0","article-title":"PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C\/EBP\u03b2 degradation to facilitate proneural-to-mesenchymal transition","volume":"41","author":"Gao","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120221_bb0990","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2174\/0113816128367551250703122830","article-title":"Angiogenesis and resistance mechanisms in glioblastoma: targeting alternative vascularization pathways to overcome therapy resistance","volume":"32","author":"Beylerli","year":"2026","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bbamcr.2026.120221_bb0995","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216862","article-title":"The mechanism of extracellular CypB promotes glioblastoma adaptation to glutamine deprivation microenvironment","volume":"597","author":"Yin","year":"2024","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb1000","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s13046-023-02927-3","article-title":"AMPK-HIF-1\u03b1 signaling enhances glucose-derived de novo serine biosynthesis to promote glioblastoma growth","volume":"42","author":"Yun","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbamcr.2026.120221_bb1005","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216801","article-title":"Hypoxia-induced TREM1 promotes mesenchymal-like states of glioma stem cells via alternatively activating tumor-associated macrophages","volume":"590","author":"Dong","year":"2024","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb1010","doi-asserted-by":"crossref","first-page":"8642","DOI":"10.1038\/s41467-025-63796-2","article-title":"Inhibition of ICAM1 diminishes stemness and enhances antitumor immunity in glioblastoma via \u03b2-catenin\/PD-L1 signaling","volume":"16","author":"Guo","year":"2025","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.bbamcr.2026.120221_bb1015","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.7150\/thno.95766","article-title":"Hypoxia-driven M2-polarized macrophages facilitate the epithelial-mesenchymal transition of glioblastoma via extracellular vesicles","volume":"14","author":"Liu","year":"2024","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb1020","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","article-title":"Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma","volume":"164","author":"Ceccarelli","year":"2016","journal-title":"Cell"},{"issue":"7015","key":"10.1016\/j.bbamcr.2026.120221_bb1025","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature"},{"issue":"7412","key":"10.1016\/j.bbamcr.2026.120221_bb1030","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nature11287","article-title":"A restricted cell population propagates glioblastoma growth after chemotherapy","volume":"488","author":"Chen","year":"2012","journal-title":"Nature"},{"issue":"7120","key":"10.1016\/j.bbamcr.2026.120221_bb1035","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb1040","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ccr.2006.02.019","article-title":"Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis","volume":"9","author":"Phillips","year":"2006","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120221_bb1045","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.gendis.2023.05.025","article-title":"Crosstalk between glioblastoma and tumor microenvironment drives proneural-mesenchymal transition through ligand-receptor interactions","volume":"11","author":"Lai","year":"2024","journal-title":"Genes Dis."},{"key":"10.1016\/j.bbamcr.2026.120221_bb1050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112820","article-title":"Research progress of mTOR inhibitors","volume":"208","author":"Chen","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb1055","doi-asserted-by":"crossref","first-page":"10784","DOI":"10.1038\/s41598-018-29062-w","article-title":"Buparlisib is a brain penetrable pan-PI3K inhibitor","volume":"8","author":"de Gooijer","year":"2018","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120221_bb1060","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11060-019-03227-7","article-title":"Phase I\/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed\/refractory glioblastoma (phase II)","volume":"144","author":"Hainsworth","year":"2019","journal-title":"J. Neuro-Oncol."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb1065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030437","article-title":"The role and therapeutic targeting of JAK\/STAT signaling in glioblastoma","volume":"13","author":"Ou","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"13","key":"10.1016\/j.bbamcr.2026.120221_bb1070","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/hepr.12504","article-title":"Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma","volume":"45","author":"Okusaka","year":"2015","journal-title":"Hepatol. Res."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb1075","article-title":"A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma","volume":"7","author":"Ellingson","year":"2025","journal-title":"Neurooncol. Adv."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb1080","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-021-03877-6","article-title":"Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial","volume":"155","author":"Saran","year":"2021","journal-title":"J. Neuro-Oncol."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120221_bb1085","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020531","article-title":"Metabolic adjustments following glutaminase inhibition by CB-839 in glioblastoma cell lines","volume":"15","author":"De Los Santos-Jim\u00e9nez","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb1090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26010427","article-title":"Glutaminase-2 expression induces metabolic changes and regulates pyruvate dehydrogenase activity in glioblastoma cells","volume":"26","author":"De Los Santos-Jim\u00e9nez","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120221_bb1095","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12031-024-02201-x","article-title":"Glutamine metabolism heterogeneity in glioblastoma unveils an innovative combination therapy strategy","volume":"74","author":"Fu","year":"2024","journal-title":"J. Mol. Neurosci."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120221_bb1100","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13816","article-title":"Tryptophan metabolic enzyme IL4I1 inhibits ferroptosis by decreasing ubiquitination of Nrf2 via I3P in glioblastoma","volume":"58","author":"Xu","year":"2025","journal-title":"Cell Prolif."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb1105","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/s41467-024-45979-5","article-title":"Trans-lesion synthesis and mismatch repair pathway crosstalk defines chemoresistance and hypermutation mechanisms in glioblastoma","volume":"15","author":"Cheng","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb1110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/neuonc\/noaf199","article-title":"DNA damage response profile distinguishes poor-acting gliomas with shared methylome signatures","volume":"28","author":"Leelatian","year":"2026","journal-title":"Neuro-Oncology"},{"issue":"5\u20136","key":"10.1016\/j.bbamcr.2026.120221_bb1115","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG inhibitors in cancer treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120221_bb1120","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","article-title":"Targeting ATR in patients with cancer","volume":"21","author":"Ngoi","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbamcr.2026.120221_bb1125","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104710","article-title":"WEE1 inhibition in cancer therapy: mechanisms, synergies, preclinical insights, and clinical trials","volume":"211","author":"Thangaretnam","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb1130","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/pharmrev.123.001026","article-title":"MDM2 inhibitors for cancer therapy: the past, present, and future","volume":"76","author":"Wang","year":"2024","journal-title":"Pharmacol. Rev."},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120221_bb1135","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb1140","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro-Oncology"},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120221_bb1145","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"399","key":"10.1016\/j.bbamcr.2026.120221_bb1150","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120221_bb1155","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.bbamcr.2026.120221_bb1160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25137174","article-title":"CAR-T cells therapy in glioblastoma: a systematic review on molecular targets and treatment strategies","volume":"25","author":"Agosti","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"Pt 2","key":"10.1016\/j.bbamcr.2026.120221_bb1165","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.semcancer.2022.06.007","article-title":"Nanomedicine for glioblastoma: progress and future prospects","volume":"86","author":"Khan","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbamcr.2026.120221_bb1170","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.6c08160","article-title":"A screening-guided biomimetic exosome-liposome hybrid nanoplatform enables pyroptosis-enhanced immune reprogramming in glioblastoma","author":"Yu","year":"2026","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb1175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbamcr.2026.120221_bb1180","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.2147\/DDDT.S296253","article-title":"Transferrin-decorated protein-lipid hybrid nanoparticle efficiently delivers cisplatin and docetaxel for targeted lung cancer treatment","volume":"15","author":"Mao","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.bbamcr.2026.120221_bb1185","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.2147\/IJN.S467876","article-title":"Albumin nanoparticle-based drug delivery systems","volume":"19","author":"Qu","year":"2024","journal-title":"Int. J. Nanomedicine"},{"issue":"9","key":"10.1016\/j.bbamcr.2026.120221_bb1190","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/1061186X.2024.2374034","article-title":"An all-in-one nanoparticle for overcoming drug resistance: doxorubicin and elacridar co-loaded folate receptor targeted PLGA\/MSN hybrid nanoparticles","volume":"32","author":"Tonbul","year":"2024","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb1195","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/acsnano.4c05906","article-title":"pH-responsive polyethylene glycol engagers for enhanced brain delivery of pegylated nanomedicine to treat glioblastoma","volume":"19","author":"Meng","year":"2025","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb1200","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-022-00699-x","article-title":"Targeting drugs to tumours using cell membrane-coated nanoparticles","volume":"20","author":"Fang","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb1205","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/138920012798356899","article-title":"The ligand nanoparticle conjugation approach for targeted cancer therapy","volume":"13","author":"Karra","year":"2012","journal-title":"Curr. Drug Metab."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120221_bb1210","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17060688","article-title":"Nanoparticles for glioblastoma treatment","volume":"17","author":"Bartusik-Aebisher","year":"2025","journal-title":"Pharmaceutics"},{"issue":"32","key":"10.1016\/j.bbamcr.2026.120221_bb1215","article-title":"Lipid-polymer nanoparticles mediate compartmentalized delivery of Cas9 and sgRNA for glioblastoma vasculature and immune reprogramming","volume":"11","author":"Zhang","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.bbamcr.2026.120221_bb1220","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116113","article-title":"Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and counteracting the immunosuppressive tumor microenvironment","volume":"171","author":"Zhao","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"18","key":"10.1016\/j.bbamcr.2026.120221_bb1225","doi-asserted-by":"crossref","first-page":"18810","DOI":"10.1021\/acs.jmedchem.5c02019","article-title":"Temozolomide-derived therapeutic strategies to overcome resistance in glioblastoma","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bbamcr.2026.120221_bb1230","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell. Mol. Immunol."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120221_bb1235","doi-asserted-by":"crossref","first-page":"151","DOI":"10.14791\/btrt.2022.0017","article-title":"Local drug delivery strategies for glioblastoma treatment","volume":"10","author":"Cha","year":"2022","journal-title":"Brain Tumor Res. Treat."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120221_bb1240","article-title":"Breaking barriers: advancements in CNS drug delivery for glioblastoma","volume":"14","author":"Al Fidawi","year":"2026","journal-title":"Med. Sci. (Basel)"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120221_bb1245","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11060-023-04552-8","article-title":"Adjuvant convection-enhanced delivery for the treatment of brain tumors","volume":"166","author":"Kreatsoulas","year":"2024","journal-title":"J. Neuro-Oncol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488926001205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488926001205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:31:28Z","timestamp":1792708288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167488926001205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":249,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0167488926001205"],"URL":"https:\/\/doi.org\/10.1016\/j.bbamcr.2026.120221","relation":{},"ISSN":["0167-4889"],"issn-type":[{"value":"0167-4889","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temozolomide resistance in glioblastoma: Multidimensional networks, core signaling hubs, and targeted therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbamcr.2026.120221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120221"}}